Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.

Abstract

Empagliflozin is an orally available, selective inhibitor of sodium glucose cotransporter 2. In this study, single oral doses of empagliflozin from 0.5 to 800 mg were not associated with any clinically significant safety concerns in healthy male volunteers. The incidence of adverse events (AEs) was similar in subjects receiving placebo (22.2%) or… (More)
DOI: 10.1002/cpdd.16

Topics

Cite this paper

@article{Seman2013Empagliflozin1, title={Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.}, author={Leo J Seman and Sreeraj Macha and Gerhard Nehmiz and Gudrun Simons and Bailuo Ren and Sabine Pinnetti and Hans J Woerle and Klaus A. Dugi}, journal={Clinical pharmacology in drug development}, year={2013}, volume={2 2}, pages={152-61} }